about
Regulatory domain selectivity in the cell-type specific PKN-dependence of cell migrationA static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes.Development and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity.Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade.The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.A high-content, cell-based screen identifies micropolyin, a new inhibitor of microtubule dynamics.Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library.Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei.Protein kinases, from B to C.Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruziComparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides.ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines.Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani.Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasisErratum for De Rycker et al., Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote AssayAuthor Correction: Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing needAnti-trypanosomatid drug discovery: an ongoing challenge and a continuing needPharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovaniPreclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibitionIdentification of inhibitors of an unconventional Trypanosoma brucei kinetochore kinase.Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discoveryIdentification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagas' diseaseSetting Our Sights on Infectious DiseasesIdentification of Novel Trypanosoma cruzi Proteasome Inhibitors Using a Luminescence-Based High-Throughput Screening AssayTrypanosoma cruzi Phosphomannomutase and Guanosine Diphosphate-Mannose Pyrophosphorylase Ligandability AssessmentThe Qi Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani
P50
Q24314028-0937B4AC-A90C-475F-B354-CF9D162D452DQ28485370-BB90DBF7-7CF7-41EE-9688-3A9B9526500BQ28548536-C8CC14AD-9DBC-470C-A27F-C02026CD0D4CQ28551393-9086B34B-878D-438A-A669-D4C70E330F6CQ30447200-E89354F7-A7F7-4CE7-AED0-97A35447B4E0Q33487405-88570B9F-EC4A-4CD3-B43C-5EE44DD23C3DQ35779255-FF38AE48-D0D4-4125-975E-30B96AD44F31Q35791902-CBFCD30A-BF62-4892-9A87-E26475B3E7FEQ36979531-D7D0F899-4B9B-4C61-B04E-931AA3AF2B44Q38919697-BEDF476F-EC07-4388-8DFE-549ED20B2FFDQ38966911-C2491EEE-01A9-4B7C-A5CF-484A138F5F7BQ39003990-7EEF8EAA-6DAA-4838-8787-63A05C8D205BQ39414703-C881790B-53CD-4570-B20E-D573E257EF4BQ44647885-46136DDF-3044-44AC-B9EB-6364E7DFB084Q47132474-DA751F3C-2499-45AA-AE2C-99BDD6437511Q56565594-738A76B4-5E27-4398-9E82-DDB1B856F2C1Q58842879-4BCBAEEE-98D7-47EC-8AFB-F5367E399CF3Q58850070-98D134D2-BF8B-4D7C-A71C-F9910C2F2E99Q58866392-F7331B7B-D723-4485-B062-6CB5CBA2BCC4Q58867156-C35B417E-CF35-4E49-AA61-EFE4E04B4EEDQ64068249-1F837E29-4DEA-4510-87A7-5F7C61F5426DQ88131729-50A7D3D1-1DC9-4C6A-9789-A15A3C9D5200Q89998156-AC081371-0751-4BA0-998B-E3DE6CE29FFFQ90661828-7448A0B3-FD04-4B15-B088-9387286C094EQ90925619-DAE03C7C-6270-4EE0-B7B1-F60E25036D29Q91750784-E33F78DA-B3A1-4EB3-82F8-28E815AE38CBQ91899271-D8BEA893-1884-4BE3-9B68-D110DD5155B9Q92575591-184945F5-48DA-4554-84BA-7AB57489C2B5Q92847998-1A3EC0E9-C977-46D7-AC61-04F7CE51D57C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Manu De Rycker
@ast
Manu De Rycker
@en
Manu De Rycker
@es
Manu De Rycker
@nl
type
label
Manu De Rycker
@ast
Manu De Rycker
@en
Manu De Rycker
@es
Manu De Rycker
@nl
prefLabel
Manu De Rycker
@ast
Manu De Rycker
@en
Manu De Rycker
@es
Manu De Rycker
@nl
P106
P1153
57193914852
6508051301
P31
P4012
P496
0000-0002-3171-3519